Transfusion-related immunomodulation

Transfusion-related immunomodulation (TRIM) refers to the transient depression of the immune system following transfusion of blood products. This effect has been recognized in groups of individuals who have undergone kidney transplantation or have had multiple miscarriages.[1] Some research studies have shown that, because of this immune depression, blood transfusions increase the risk of infections and cancer recurrence. However, other studies have not shown these differences and the degree of impact transfusion has on infection and tumor recurrence is not well understood.[2] The Blood Products Advisory Committee of the Food and Drug Administration recommends that all transfused blood products undergo leukocyte reduction in order to offset the contribution of donor white blood cells to immune suppression.[3]

References

  1. ↑ Gatenby PA, Cameron K, Simes RJ, Adelstein S, Bennett MJ, Jansen RP, Shearman RP, Stewart GJ, Whittle M, Doran TJ (Mar 1993). "Treatment of recurrent spontaneous abortion by immunization with paternal lymphocytes: results of a controlled trial". Am J Reprod Immunol. 29 (2): 88–94. PMID 8329110.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ↑ Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP (Feb 1999). "Transfusion medicine. First of two parts--blood transfusion". N Engl J Med. 340 (6): 438–47. doi:10.1056/NEJM199902113400606. PMID 9971869.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ↑ American Association of Blood Banks. BPAC recommends universal leukoreduction. AABB News Briefs 1998;20(11):16.
This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.